Pyrazinamide
Rifater (pyrazinamide) is a small molecule pharmaceutical. Pyrazinamide was first approved as Pyrazinamide on 1982-01-01. It is used to treat mycobacterium infections and tuberculosis in the USA.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Isoniazid
+
Pyrazinamide
+
Rifampin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RIFATER | Sanofi | N-050705 DISCN | 1994-05-31 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| pyrazinamide | ANDA | 2023-03-31 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| mycobacterium infections | — | D009164 | A31.9 |
| tuberculosis | EFO_0000774 | D014376 | A15-A19 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J04: Antimycobacterials
— J04A: Drugs for treatment of tuberculosis
— J04AK: Other drugs for treatment of tuberculosis in atc
— J04AK01: Pyrazinamide
— J04AM: Combinations of drugs for treatment of tuberculosis
— J04AM05: Rifampicin, pyrazinamide and isoniazid
— J04AM06: Rifampicin, pyrazinamide, ethambutol and isoniazid
HCPCS
No data
Clinical
Clinical Trials
77 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 5 | 13 | 11 | 3 | 6 | 35 |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 15 | 8 | 2 | 4 | 27 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 3 | 4 | 4 | 5 | 16 |
| Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | 4 | 7 | 1 | 1 | 11 | |
| Spinal tuberculosis | D014399 | A18.01 | — | — | — | 1 | — | 1 | |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv | D006678 | O98.7 | — | 2 | 1 | — | — | 3 | |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 1 | 2 | — | — | 2 |
| Extensively drug-resistant tuberculosis | D054908 | — | 1 | 2 | — | — | 2 | ||
| Anterior uveitis | D014606 | EFO_1000811 | — | — | 1 | — | — | 1 | |
| Bacterial infections | D001424 | A49 | — | — | 1 | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Body weight changes | D001836 | — | — | — | — | 1 | 1 | ||
| Motor activity | D009043 | EFO_0003940 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PYRAZINAMIDE |
| INN | pyrazinamide |
| Description | Pyrazinecarboxamide is a monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis. It has a role as an antitubercular agent and a prodrug. It is a member of pyrazines, a N-acylammonia and a monocarboxylic acid amide. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | NC(=O)c1cnccn1 |
Identifiers
| PDB | — |
| CAS-ID | 98-96-4 |
| RxCUI | 8987 |
| ChEMBL ID | CHEMBL614 |
| ChEBI ID | 45285 |
| PubChem CID | 1046 |
| DrugBank | DB00339 |
| UNII ID | 2KNI5N06TI (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 15,822 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
65 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more